Introduction
Ph-positive leukemias, including chronic myelogenous leukemia (CML) and a subclass of acute lymphoblastic leukemia (ALL) are caused by the fusion of the BCR gene to the ABL proto-oncogene 1, 2 . The P190 type of Bcr/Abl protein is associated with Ph-chromosome positive ALL. Prognosis for this type of cancer is poor [3] [4] [5] . Even though the tyrosine kinase inhibitor Imatinib is effective in treatment of chronic phase CML, Ph-positive ALL responds only transiently to treatment with this drug 6, 7 . Also, responses of CML patients in blast phase to the standard dose of Imatinib may be transient and resistance to this drug can develop [8] [9] [10] . Other treatments are therefore clearly needed.
A class of molecules that interfere with the activity of the enzyme farnesyltransferase (FT) has emerged in preclinical models as a possible alternative treatment for this type of leukemia [11] [12] [13] . Experiments in mouse models suggest the drug may be very effective; in addition, cells of patients that are resistant to Imatinib appear to be sensitive to farnesyltransferase inhibitors (FTIs) [14] [15] [16] [17] .
Experience with most anti-cancer drugs including Imatinib 18, 19 has shown that invariably, in some patients, resistance against such drugs arises. FTIs are currently in phase I and II clinical trials for a variety of cancers including leukemias [20] [21] [22] [23] . However, if resistance against such drugs can develop is unknown. In view of the potential use of FTIs in the treatment of Ph-positive ALL, we set out to explore possible mechanisms of drug resistance against FTIs. We subjected cells expressing Bcr/Abl P190 that were derived from a transgenic mouse model to increasing concentrations of the FTI SCH66336 (Lonafarnib) and obtained a fully drug-resistant derivative. The current study describes a novel mechanism of resistance against the FTI SCH66336 and other small molecule signal transduction inhibitors.
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From
Materials and Methods

Isolation of B-1 cells, generation of B-1R cells and drug treatment.
Bin-1 (B-1) cells were grown in culture from the lymphoma of a 7 ½ month old male P190 BCR/ABL transgenic mouse from the 623 line 24, 25 . Briefly, the lymphoma was dissected into several small pieces, which were then pressed between the frosted parts of two microscope slides and washed with PBS supplemented with 1 U/ml heparin. The cell suspension was filtered through a 35-µm nylon mesh. B-1 cells were grown in McCoy's 5A Modified Medium (Gibco-BRL) with 15% fetal calf serum (FCS; heat-inactivated), 110 mg/ml sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, and freshly added 50 M -mercaptoethanol and 10 ng/ml murine IL-3. Cells were maintained on irradiated (10 000 rad) primary mouse embryonic fibroblast feeder layers.
To isolate cells that were able to tolerate increased concentrations of FTI, the B-1 cells were grown on mitotically inactivated fibroblasts over a period of 3 months in the presence of DMSO or DMSO with 0.05 -16 KM SCH66336. The medium was refreshed every 2-3 days with inclusion of fresh SCH66336.
Lymphoma cells were exposed to a starting concentration of 0.05 KM SCH66336, which killed about half of the cells. When the cells stopped dying and resumed proliferation, which took about one to two weeks, the doses of SCH66336 were doubled. After the final adaptation, to 16 KM SCH66336, all cells were harvested on the same day after an identical period after refreshing of the medium. RNA and protein was isolated.
Cells were exposed to FTI-276 (10 KM), GGTI-298 (20 KM) (both from Preparation of RNA and Northern blotting.
RNAs were extracted using Trizol according to the supplier's specifications (Invitrogen). Samples in loading buffer with ethidium bromide (15 Kg total RNA) were run on a 1.0% agarose gel containing 20 mM guanidine thiocyanate 27 in 1xTBE buffer. Gels were blotted in 20xSSPE to Hybond-N (Amersham). The ATP11a probe for Northern and Southern blotting was generated using the primers described below for RT-PCR using total mouse heart RNA. Hybridization was for 24 hours in 50% deionized formamide, 5xSSC, 5xDenhardts, 0.5% SDS, 100 Kg/ml herring sperm DNA, 10% dextran sulphate, at 42°C; the final posthybridization wash was at 0.01xSSC at 65°C. 
ATP11a cDNAs.
The murine and human ATP11A genes (GeneCard identifier GC13P112526) appear to encode multiple spliced forms, presumed to result in proteins with different N-and C-terminal ends. These include for the N-terminus: We obtained a full-length human ATP11A cDNA clone FB2768 (XM_085028 version 2) from Origene. This clone has an insert of around 5.5 kb, with the insert directionally cloned between the Eco RI and Sal I sites of the pCMV-XL4 vector.
Transfections, cell cycle analysis and Western blots.
To verify that the ATP11A cDNA clone FB2768 expressed a protein, we inserted it in frame with the Xpress tag of pcDNA and the presence of protein was verified after transfection and Western blotting.
To test for activity, we used the untagged ATP11A cDNA clone FB2776. 293A Del Villar et al 29, 31 reported that resistance to FTIs can be generated and the substrate specificity of the FT enzyme can be changed by point mutations in specific residues of the FT subunit. To investigate whether the substrate For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From expression levels of ATP11a (ATP11a/actin = 0.16) as well as lower ABCA1 levels ( Figure 3C ). This suggests a correlation between relative resistance to SCH66336 and ATP11a levels. Figure 5B ). We transfected these cells with two siRNAs specific for murine ATP11a and with a non-specific siRNA. As shown in Figure 5A , Northern blot analysis showed that NIH3T3 cells transfected with the non-specific siRNA clearly express ATP11a mRNA and that ATP11a expression was decreased by the ATP11a-specific siRNAs. Real-time RT-PCR further confirmed a substantial reduction in ATP11a mRNA levels by the specific siRNAs 36 hours after transfection ( Figure 5B ).
Next, we treated cells transfected with the non-specific and the ASU anti-ATP11a siRNA with 50 KM SCH66336 24 hours after transfection, and measured cell viability 48 hours later. As shown in Figure 5C , the transfectants that expressed the ASU siRNA were more sensitive to SCH66336 than the cells transfected with the non-specific siRNA. Based on its sequence, ATP11a belongs to an extended family of ABC transporters that includes proteins conferring the multi-drug resistance phenotype to cancer cells 32 . We therefore asked if the overexpression of this putative ABC transporter would also be correlated with resistance to other drugs. SCH66336 is a tricyclic FTI 35 . Therefore, we tested FTI-276, a non-peptidomimetic FTI similar to SCH66336 but with a different ring structure. As shown in Figure 6A , the B-1R cells were also resistant to treatment with 10 KM FTI-276 for 48 hours as compared to the B-1S cells. only.
For . Because inhibitors of GGT (GGTIs) are also being considered for the treatment of leukemia/lymphoma 37, 38 we tested the GGTI-298, a compound structurally similar to FTI SCH66336. As shown in Figure 6B , the B-1R cells which are resistant to SCH66336 showed very little decrease in viability when exposed to 20 KM GGTI-298, whereas around 70% of the B-1S cells were killed. We also 
Discussion
In the current study we intentionally made leukemic lymphoblasts drug resistant by exposing them to gradually increased concentrations of a relatively new drug that is currently being tested in human clinical trials for a variety of cancers.
During induction of drug resistance, cells were kept in contact with stroma to model the interactions occurring in the bone marrow of a patient during drug treatment. We found that, although the cells initially were very sensitive to 0.1 KM SCH66336, it was possible to derive progeny from them that proliferated in the presence of 16 KM, a 160-fold increased concentration.
The one other study that examined FTI-resistance, against Zarnestra (R115777), in an established human colon cancer cell line, did not report the mechanism that would cause the resistance 40 . They suggested but did not investigate the possibility that an acquired mutation in the farnesyltransferase enzyme 29 could have caused this phenotype. This was clearly not the cause of FTI resistance in the current study, and instead we found significantly decreased expression of the ABC transporter ABCA1 and markedly increased upregulation of a novel protein also belonging to the ABC transporter family, ATP11a.
ABCA1 is critical for cholesterol, aminophospholipid and bile salt transport, and is mutated in Tangier disease   41 but is not known to be involved in the transport of drugs. Since ABCA1 expression is downregulated when cells are exposed to geranylgeranyl phosphatase, an inhibitor of the geranylgeranyl transferase (GGT) enzyme 42 , the decreased expression of ABCA1 found in the current study may relate to a possible altered balance between FT and GGT activity, or the products of these enzymes, in cells exposed to an inhibitor of FT. Alternatively, since SCH66336 inhibits the function of multidrug resistance proteins MDR1/ABCB1 and MRP1/ABCC1 and MRP2/ABCC2 43 , the drug could affect the activity of multiple members of the ABC transporter family via an unknown common mechanism. Therefore, the significance of the decreased levels of ABCA1 on the drug resistant phenotype, if any, is currently not clear.
We found that the levels of ATP11a mRNA were increased up to 100-fold in the cells intentionally made SCH66336-resistant. The ATP11a gene product 44 . Based on its primary structure and homology to domains in other family members, ATP11a is predicted to have ten transmembrane domains and one ATP-binding site. Since ATP11a (also designated as ATPase Class VI, type 11A) is expressed in many different types of mouse tissues such as heart, brain, muscle and liver 33 as well as in human blood and colon (UniGene Hs. 508757), if it is a transporter, it is likely to have a transport function more general than that in, for example, primary bile formation.
We found that modulation of ATP11a levels through either overexpression or siRNA knockdown caused cells to be less sensitive or more sensitive to SCH66336. One explanation for these findings is that ATP11a is able to directly transport SCH66336 out of cells. However, if ATP11a is indeed a drug transporter, the question arises why its effect in the transfected 293 and 3T3 cells was relatively modest. A number of factors could contribute to these moderate responses: (1) to begin with, drugs such as SCH66336 have a much less acute cytotoxic effect on cells in general, in comparison with very cytotoxic drugs such as vincristine. This is clearly seen in vivo in animal models 13 or in human patients 45 . Other investigators, working with SCH66336 in vitro, have also described that the drug slows proliferation 12 or is cytostatic for some melanoma We conclude that overexpression of ATP11a confers on malignant lymphoblasts, either directly or indirectly, the increased ability to survive in the presence of small molecule inhibitors. Although the normal cellular substrates of ATP11a are not known, the gene appears to be ubiquitously expressed, including alternatively spliced forms that potentially encode transporters with different substrate specificities (see Materials and Methods). Also, we found that the levels of ATP11a were spontaneously increased in lymphoblastic leukemia cells that had been passaged in a nude mouse without exposure to SCH66336.
Therefore, some types of cancer may naturally express high levels of ATP11A and could be already partly resistant against small molecule inhibitor-type drugs before treatment is started. Also, our study indicates that elevated levels of ATP11a gene expression could be induced in some types of cancer because of treatment with drugs such as SCH66336. It will be therefore of interest to investigate how this gene is regulated on a transcriptional level and whether it is possible to silence its expression in leukemic cells. In addition, ATP11a levels may have prognostic value in assessing the likelihood of success before initiation of treatment with certain small molecule inhibitors in cancer drug therapy.
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